Compositions and methods for cardiac therapy
Inventors
Christman, Karen • Singelyn, Jennifer • DeQuach, Jessica
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9789224-B2
Publication Date
2017-10-17
Expiration Date
Abstract
Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.
Core Innovation
The disclosed invention provides a cardiac therapy composition that includes digested, decellularized extracellular matrix derived from cardiac tissue. The extracellular matrix has a pore size of about 30 to 40 microns and the composition is injectable through a catheter with an inner diameter of 25G or smaller. The composition further comprises glycosaminoglycan in a concentration between about 60 to 120 µg/mL of the extracellular matrix.
The disclosure also provides tissue culture device concepts for in vitro tissue culture. The device comprises a substrate and a composition that includes digested, decellularized extracellular matrix derived from cardiac tissue with a pore size of about 30 to 40 microns. In the device, the extracellular matrix comprises from about 10 to about 20 µg of glycosaminoglycans per mg of the extracellular matrix.
The invention is directed to cardiac therapy and regenerative-related outcomes after myocardial infarction, including functional improvements and arrhythmia-related conduction-block effects. The provided compositions and devices are characterized by specified pore size and glycosaminoglycan content, and are formulated for catheter-deliverable use or for in vitro tissue culture.
Claims Coverage
The partial content identifies two independent claims covering a catheter-injectable composition and a tissue culture device. Across the independent claims, the main inventive features are the defined cardiac-derived digested, decellularized ECM structure, glycosaminoglycan concentration or content, catheter injectability, and a substrate-based ECM-containing construct for in vitro tissue culture.
Catheter-injectable digested, decellularized cardiac ECM composition with defined pore size and glycosaminoglycan concentration
A composition comprising digested, decellularized extracellular matrix derived from cardiac tissue, the extracellular matrix having a pore size of about 30 to 40 microns, wherein the composition is injectable through a catheter with an inner diameter of 25G or smaller, and wherein the extracellular matrix comprises glycosaminoglycan in a concentration of between about 60 to 120 µg/mL of the extracellular matrix.
Tissue culture device using cardiac ECM composition with defined pore size and glycosaminoglycan loading
A tissue culture device comprising a composition comprising digested, decellularized extracellular matrix derived from cardiac tissue, the extracellular matrix having a pore size of about 30 to 40 microns, and a substrate, wherein the tissue culture device is used for in vitro tissue culture, and wherein the extracellular matrix comprises from about 10 to about 20 µg of glycosaminoglycans per mg of the extracellular matrix.
Overall, claim coverage centers on cardiac-derived digested, decellularized ECM with a defined pore size of about 30 to 40 microns and defined glycosaminoglycan levels, with one independent claim requiring catheter injectability through 25G-or-smaller catheters and the other requiring a substrate-based device for in vitro tissue culture.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Cardiac therapy after myocardial infarction, including functional improvements post-myocardial infarction.
Arrhythmia conduction block.
In vitro tissue culture using the stated tissue culture device.
Interested in licensing this patent?